Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 61 clinical trials
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults With Bacteremia Due to Staphylococcus Aureus (diSArm)

Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus

staphylococcus
antibiotics
blood culture
antibiotic therapy
bacteremia
  • 0 views
  • 28 Oct, 2022
  • 10 locations
Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins

Belgium and UK) vs a carbapenem antibiotic (meropenem) in adults with bacteraemia due to third-generation cephalosporin-resistant Enterobacteriaceae. The duration of treatment will be between 7 and

antibiotics
ceftazidime
meropenem
cephalosporins
ceftriaxone
  • 0 views
  • 20 Oct, 2021
  • 32 locations
Bacteremia From Periodontal Treatment to Elucidate the Underpinnings of Sepsis

Approximately 40,000 Swedes suffer from sepsiseach year, about 20% die. Biomarkers that are sensitive to current or previous bacteremia are needed in the treatment of sepsis. Bacteremia from

antibiotics
antimicrobial agent
antimicrobials
Accepts healthy volunteers
bacteremia
  • 2 views
  • 19 Apr, 2022
  • 1 location
AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED STUDY TO ESTIMATE THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) VERSUS BEST AVAILABLE TREATMENT (BAT) IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE PATHOGENS IN CHINESE ADULTS

This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types (Hospital Acquired Pneumonia [HAP] (including Ventilator-Associated Pneumonia [VAP]); Complicated Urinary-Tract Infection [cUTI]; Complicated Intra-Abdominal Infection [cIAI]; Bloodstream Infection [BSI]) …

antibacterial
ceftazidime
meropenem
amikacin
fosfomycin
  • 0 views
  • 21 Oct, 2022
  • 14 locations
Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia

Gram negative bacteremia with a urinary tract source of infection (GNB). Five days after initiation of antimicrobial therapy for GNB, participants are randomized 1:1 to parallel treatment arms

  • 22 views
  • 26 Jan, 2021
  • 12 locations
  • 12 views
  • 25 Oct, 2022
  • 18 locations
Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia (CALIF)

CALIF study is a monocentric observational study which aim is to analyse the value of adding procalcitonin (PCT, a pre-hormon increased in bacterial infection and septicaemia) in the management of chemo-induced febrile neutropenia occurring in patient with solid tumour. Febrile neutropenia will be managed according to international guidelines. PCT will …

  • 10 views
  • 30 Jan, 2022
  • 1 location
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Enterobacteriaceae infections with IMI/REL including in bacteremia, and to analyze treatment outcomes in use of IMI/REL for KPC-producing infections compared to historical clinical outcome data with CZA and MVB use

antibiotics
ceftazidime
cilastatin
bacteremia
imipenem
  • 8 views
  • 12 Jul, 2022
  • 1 location
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

Many patients with CLL have a weakened immune system due to their disease. It increases their risk of developing serious, treatment-requiring infections such as blood poisoning or pneumonia

hepatitis b core antibody
venetoclax
acalabrutinib
cancer
neutrophil count
  • 9 views
  • 26 Feb, 2022
  • 3 locations
A Controlled Human Pneumococcal Infection Model (PIM) Study (PIM)

Infection with Streptococcus pneumoniae (the pneumococcus) is the leading cause of pneumonia, bacterial meningitis and bacteraemia worldwide in the very young and the elderly. Although

antibiotics
vaccination
meningitis
Accepts healthy volunteers
pneumonia
  • 0 views
  • 17 Jun, 2022
  • 1 location